Neuroscience isn't currently one of the top strategic R&D priorities at GSK, but a new alliance with ABL Bio adds to the sense that its focus may be shifting. The UK-headquartered pharma group is ...

A 'hybrid' therapy for Parkinson's disease developed by Remepy, combining a drug with a digital therapeutic, has shown ...

A report that the NHS is considering scaling back its recruitment drive and deploying greater use of AI to plug the gap has ...

UK-based GHO and CBC Group of Singapore – have announced a merger to create a massive player in the category with $21 billion ...

The WHO has held a closed expert meeting to identify potential vaccines for the Bundibugyo species of Ebola that is causing ...

Fresh from agreeing a wide-ranging alliance with Regeneron worth up to $2.3 billion, Parabilis Medicines has decided to ...

Underlying many of these challenges is a broader industry mindset that can, at times, slow progress. There is often a ...

A phase 2 trial of Sanofi's experimental therapy for alpha-1 antitrypsin deficiency (AATD) has raised the hope of an ...

The US Supreme Court has rejected lawsuits from pharma groups challenging Medicare's drug pricing negotiation powers, saying ...

A research consortium that aims to make the UK a leader in AI-driven drug discovery, OpenBind, has hit its first major ...

The preliminary agenda has just been released! Returning as the largest and definitive ADC congress, the 17th World ADC San ...

Regeneron has reported that its fianlimab antibody targeting LAG-3, an immune checkpoint proposed as a cancer target, has ...